Grant: Engage Grants Program
Institut national de la recherche scientifique
$25,000.00
Method development to investigate the assembly of a ternary holoreceptor complex**
FY 2018-19
Summary
The grant proposal consists in establishing a method to quantify binding affinities between a signaling protein and a combination of receptors and coreceptors in vitro. Paraza Pharma is a fully integrated research organization developing biotechnological application. The company aims to develop novel methods for the purification of secreted and membrane integral proteins that contribute to signaling and cellular communication at the cell surface; another aspect of the project aims at elucidating the formation of an holoreceptor transducing signal from the extracellular milieu to the cytoplasm upon binding of a signaling protein with its putative receptor/coreceptor complex. Understanding how a signaling protein binds to a holoreceptor complex composed of a combination of receptors and coreceptors remains a fundamental question and a technical challenge raised by Paraza Pharma. Such project requires highly sensitive biophysical methods to measure binding affinities between the diverse protein components of the signaling pathway, as well as it requires specialized expertise in the field of membrane proteins, which are considered challenging samples due to their intrinsic instability and difficulty to manipulate in vitro. Dr. Calmettes, an expert in membrane protein characterization and macromolecular crystallography, will develop for Paraza Pharma a method to produce and purify membrane-signal-transducing proteins and to quantify their binding affinities with a cognate signaling protein. The experimental design to be developed is highly relevant for the Canadian industry and the advancement of knowledge in Canada; it is anticipated to open new avenues for the development of future applications in biotechnology, bioscience and bio-industrial sectors in Canada.
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
533921-2018
Name nom
Calmettes, Charles
Department département
INRS-Institut Armand-Frappier, Centre
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5407
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Receptors
Research subject fr
Récepteurs
Partie
1
Nb partie
1
Application title
Method development to investigate the assembly of a ternary holoreceptor complex**
Keyword
NSERC
Application summary
The grant proposal consists in establishing a method to quantify binding affinities between a signaling protein and a combination of receptors and coreceptors in vitro. Paraza Pharma is a fully integrated research organization developing biotechnological application. The company aims to develop novel methods for the purification of secreted and membrane integral proteins that contribute to signaling and cellular communication at the cell surface; another aspect of the project aims at elucidating the formation of an holoreceptor transducing signal from the extracellular milieu to the cytoplasm upon binding of a signaling protein with its putative receptor/coreceptor complex. Understanding how a signaling protein binds to a holoreceptor complex composed of a combination of receptors and coreceptors remains a fundamental question and a technical challenge raised by Paraza Pharma. Such project requires highly sensitive biophysical methods to measure binding affinities between the diverse protein components of the signaling pathway, as well as it requires specialized expertise in the field of membrane proteins, which are considered challenging samples due to their intrinsic instability and difficulty to manipulate in vitro. Dr. Calmettes, an expert in membrane protein characterization and macromolecular crystallography, will develop for Paraza Pharma a method to produce and purify membrane-signal-transducing proteins and to quantify their binding affinities with a cognate signaling protein. The experimental design to be developed is highly relevant for the Canadian industry and the advancement of knowledge in Canada; it is anticipated to open new avenues for the development of future applications in biotechnology, bioscience and bio-industrial sectors in Canada.